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Background: Plasmodium falciparum infections adversely affect pregnancy. Anti-malarial treatment failure is common.
The objective of this study was to examine the duration of persistent parasite carriage following anti-malarial treatment
in pregnancy.
Methods: The data presented here are a collation from previous studies carried out since 1994 in the Shoklo Malaria
Research Unit (SMRU) on the Thailand-Myanmar border and performed using the same unique methodology detailed
in the Materials and Methods section. Screening for malaria by microscopy is a routine part of weekly antenatal care
(ANC) visits and therapeutic responses to anti-malarials were assessed in P. falciparum malaria cases. Women with
microscopy confirmed P. falciparum malaria had a PCR blood spot from a finger-prick sample collected. Parasite DNA
was extracted from the blood-spot samples using saponin lysis/Chelex extraction method and genotyped using
polymorphic segments of MSP1, MSP2 and GLURP. Recurrent infections were classified by genotyping as novel,
recrudescent or indeterminate. Factors associated with time to microscopy-detected recrudescence were analysed
using multivariable regression techniques.
Results: From December 1994 to November 2009, 700 women were treated for P. falciparum and there were 909
recurrent episodes (481 novel and 428 recrudescent) confirmed by PCR genotyping. Most of the recurrences, 85 %
(770/909), occurred after treatment with quinine monotherapy, artesunate monotherapy or artesunate-clindamycin. The
geometric mean number of days to recurrence was significantly shorter in women with recrudescent infection, 24.5
(95 %: 23.4-25.8), compared to re-infection, 49.7 (95 %: 46.9-52.7), P <0.001. The proportion of recrudescent P. falciparum
infections that occurred after days 28, 42 and 63 from the start of treatment was 29.1 % (124/428), 13.3 % (57/428) and
5.6 % (24/428). Recrudescent infections ≥100 days after treatment occurred with quinine and mefloquine monotherapy,
and quinine + clindamycin and artesunate + atovaquone-proguanil combination therapy. Treatments containing an
artemisinin derivative or an intercalated Plasmodium vivax infection increased the geometric mean interval to
recrudescence by 1.28-fold (95 % CI: 1.09-1.51) and 2.19-fold (1.77-2.72), respectively. Intervals to recrudescence
were decreased 0.83-fold (0.73-0.95) if treatment was not fully supervised (suggesting incomplete adherence) and
0.98-fold (0.96-0.99) for each doubling in baseline parasitaemia.
Conclusions: Prolonged time to recrudescence may occur in pregnancy, regardless of anti-malarial treatment. Long
intervals to recrudescence are more likely with the use of artemisinin-containing treatments and also observed with
intercalated P. vivax infections treated with chloroquine. Accurate determination of drug efficacy in pregnancy requires
longer duration of follow-up, preferably until delivery or day 63, whichever occurs last.* Correspondence: rose@shoklo-unit.com
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Fig. 1 Study flow
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In order to reduce malaria-related maternal mortality in a
low-transmission area where multidrug-resistant (MDR)
strains of Plasmodium falciparum are prevalent, frequent
screening and treatment of all positive malaria episodes is
required. This has been a focus area of the antenatal
clinics (ANCs) of Shoklo Malaria Research Unit (SMRU)
on the Thailand-Myanmar border [1, 2]. In 1994, PCR
genotyping of P. falciparum parasite recurrence was intro-
duced to distinguish novel or new infections from recru-
descent infections [3]. This is the accepted method for
reporting trials of anti-malarial drug efficacy [4, 5]. PCR
genotyping results of P. falciparum at SMRU have been
published within the context of treatment efficacy trials
in pregnant women [6–11] and in non-pregnant pa-
tients [12, 13]. The longest reported time to recrudes-
cence confirmed by PCR genotyping in non-pregnant
patients is 62 days [3] but the duration of follow-up in P.
falciparum anti-malarial drug trials is limited to 63 days
[4]. In pregnancy, when a woman may naturally follow
antenatal care for an extended period, much longer car-
riage times have been reported: 133 days in Malawi [14],
187 days in Mozambique [15], 85 days [7], 98 days [10]
and 121 days [3] on the Thailand-Myanmar border.
In the era of malaria therapy from the 1920s to the
1950s, and the volunteer studies conducted to assess
new anti-malarial drugs conducted in Australia and the
USA, natural infections in previously non-immune sub-
jects were observed to last for many months. Transfu-
sion malaria infections acquired from donors who had
left the endemic area years previously were also docu-
mented [16]. In the early 1950s, Eyles and Young [17]
reported the duration of incompletely treated, artificial
P. falciparum infections (South Carolina strain) in
neurosyphilis patients. The average duration of infection
was 222 days with three of the infections persisting for
more than one year, and the longest 480 days. In a simi-
lar report with the Panama strain of P. falciparum there
were 23 incompletely treated infections which persisted
for an average of 280 ± 20 (range 114 to 503) days, with
four cases persisting for more than one year [18]. These re-
ports occurred long before the PCR genotyping technique
was introduced [19, 20] but the concept of prolonged
asymptomatic carriage of P. falciparum is well established
[21]. The longest recorded persistence of P. falciparum in
an individual is 13 years [16]. Here P. falciparum genotyp-
ing was used to examine the duration of persistent P. falcip-
arum carriage in pregnant women and examine the factors
associated with time to recrudescence.
Methods
Study site and population
Pregnant women in this series attended the weekly ANC
of SMRU on the northwestern border of Thailand. Inthis hilly, forested area malaria transmission is low and
seasonal (estimated entomological inoculation rate <2)
in the whole population, including pregnant women
[22]. Acquired immunity is poorly protective and severe
malaria is common at all ages, especially in pregnant
women [22]. At the start of the research programme,
maternal mortality from falciparum malaria was high:
estimated 1,000 maternal deaths per 100,000 live births
[2]. Women are invited to come to the ANC as soon as
they are aware of their pregnancy. All women attending
consultation are screened weekly for malaria as the only
effective strategy to prevent maternal death [1]. Prophylac-
tic vitamins (ferrous sulphate, folic acid and vitamin B1)
are provided to all women attending for consultation.
Haematocrit levels are measured at two weekly intervals
and anaemic women (haematocrit <30 %) receive treat-
ment doses of ferrous sulphate and folic acid. In the case
of severe symptomatic anaemia (haematocrit <20 %)
screened blood transfusions are provided.
Treatment of Plasmodium falciparum in pregnancy
This study spans 15 years during which treatment of
falciparum malaria has changed from monotherapy to
artemisinin-based combination therapy (ACT) (Fig. 1).
Quinine based therapy has always been the first-line treat-
ment for uncomplicated malaria in the first trimester. Quin-
ine was also used throughout pregnancy until artemisinins
were recommended in 2005 for routine first-line therapy in
the second and third trimesters for uncomplicated malaria.
Quinine-clindamycin (a non-artemisinin based combination
therapy) has been used almost exclusively in the first trimes-
ter since its introduction in 2006.
Treatment doses for uncomplicated malaria infections
were prescribed as follows: quinine three times daily
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ceutical Organization) for seven days; artesunate (outside
the first trimester) once daily (usually 2 mg /kg) for
seven days (total dose 10–16 mg/kg, Guilin, PRC);
artemether-lumefantrine (artemether 20 mg and lume-
fantrine 120 mg, Novartis, Basel, Switzerland): four tablets
twice daily for three days, mefloquine 25 mg/kg stat dose
or as a split dose (15 mg/kg and 10 mg/kg on consecutive
days); dihydroartemisinin-piperaquine once daily for three
days (DHA 3 mg/kg, PPQ 15–17 mg/kg, Holley Pharm
PRC); artesunate (4 mg/kg/day) combined to atovaquone-
proguanil (atovaquone 20 mg/kg/day and 8 mg/kg/d) for
three days (Malarone, Glaxo-Wellcome, Dartford, UK).
Since 2007, clindamycin was combined with artesunate or
quinine at a dose of 5 mg/kg three times daily (in practice
in most women this was 300 mg three times daily, Siam
Bheasach). Chloroquine (Government Pharmaceutical
Organization, Thailand) was given once a day for three
days, with a dose of 10 mg base/kg/day for two days and
5 mg base/kg/day on the third day, for Plasmodium
vivax. Treatment administration was either unsuper-
vised, when a pregnant woman was not admitted for
treatment, or supervised when the initial doses or all of
the doses were administered by a health worker and the
pregnant woman was observed for vomiting. Pregnant
women who vomited within 30 min of their dose were
re-administered a full dose and those who vomited
within 30 to 60 min of initial dosing were re-administered
half the dose.
Contrary to the changes in treatment over time there
has been no change in the unique methodology applied
to pregnant women in this area including the screening
by microscopy for malaria offered at every antenatal visit
during pregnancy, in the basic data collected at the time
of each malaria episode and in the way the sample is col-
lected. At the time of each malaria episode the date,
body temperature, history of fever in the previous 48 h,
parasitaemia, haematocrit, gestational age of the preg-
nancy, and malaria history were recorded. After micros-
copy diagnosis and before treatment, fresh blood from a
finger-prick sample was used to make three blood spots
(approximately 30 μl each) on a strip of 3 M filter paper.
This was dried overnight before DNA extraction the
next day.
Definitions
Symptomatic malaria was defined as slide-confirmed
parasitaemia with a history of fever in the previous 48 h
or a measured axillary or aural temperature ≥37.5 °C
[23]. Asymptomatic malaria was defined as slide-
confirmed parasitaemia without any history of fever and
a measured temperature <37.5 °C. The gestational age
at the time of the malaria episode was determined by
ultrasound [24], the Dubowitz newborn examination[25] or by the fundal height formula developed for this
population [26]. Treatments were classified as mono-
therapy when given without any other anti-malarial.
Mefloquine and piperaquine were categorized as ‘long-
acting’ drugs, lumefantrine and atovaquone-proguanil
as medium-acting drugs and the remainder as short
acting.
For recrudescence risk factor based analysis anti-
malarial therapies were grouped into artemisinin based:
including ACT and artesunate monotherapy and non-
artemisinin based including combinations such as quinine
and clindamycin or monotherapy such as mefloquine.
Plasmodium falciparum PCR genotyping
Plasmodium falciparum infection from consecutive malaria
episodes during pregnancy was analysed by using the three
loci genotypes: MSP1, MSP2 and GLURP. Nested PCR was
the amplification strategy used to genotype P. falciparum
and this is explained in detail elsewhere [3, 27, 28]. A para-
site infection with the same three-locus genotype pre- and
post-treatment was considered a recrudescence. Infections
which differed pre- and post-treatment were denoted as
novel (or new) infections. Infections that could not be clas-
sified as recrudescent or new were denoted as indetermin-
ate. Only patients who became microscopy smear negative
following treatment were included in the analysis. The time
to the next patent infection was calculated by the difference
in days from the date treatment started until the date of the
first recurrence detected by microscopy with active weekly
screening.
Statistical analysis
Continuous variables were described using median (range)
and categorical variables using frequency (percentage).
The distribution of the number of days to recurrence of P.
falciparum infection was positively skewed (Fig. 2) and
therefore natural logarithm (loge) transformed. Linear re-
gression models were fitted to the loge transformed out-
come, and either geometric means or ratios of geometric
means were derived. Separate sub-group analyses were
performed for women with recrudescent infection(s) and
women with novel infection(s). In the multivariable linear
regression analyses, a risk factor was deemed to be asso-
ciated with the loge transformed outcome if the p-value
was below the nominal significance level of 0.1; multi-
collinearity between each of the covariates (i.e., risk fac-
tors) was assessed using variance inflation factors (VIFs;
all <2); and all estimates derived from the regression
analyses were adjusted for age (years), weight (kg), and
study period categorized into four three-year intervals
(1994–97, 1998–2001, 2002–05, 2006–09). As resist-
ance appears with increasing years of drug use, e.g., ar-
temisinin, and as the cohort was conducted over many
years with different numbers of women available in
Fig. 2 Frequency of PCR-confirmed novel (white) and recrudescent (black) Plasmodium falciparum infections for each follow-up week from day 7
of treatment
Table 1 Distribution of variables measured in 700 pregnant
women before treatment of the primary Plasmodium falciparum
infection
Characteristic Na Median [range] or %
Age (years) 700 24.5 [14–45]
Maternal weight (kg) 692 47 [30–78]
Haematocrit (%) 660 31 [12–48]
Parasitaemia/μL 699 3,216 [16.4-4,768]
Temperature (°C) 642 36.8 [35.0-40.4]
Symptomatic 654 67.3
aN, number of observations
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even distribution of women in each block, so time could
be controlled for in regression analysis. To account for
the correlation between the number of days to recur-
rence of multiple P. falciparum infections during a sin-
gle pregnancy, robust standard errors were calculated
using the Huber-White sandwich estimator. Tests for
linear trends were performed by fitting a linear model
to the outcome variable with the categorical covariate
treated as pseudo continuous. Proportions were com-
pared using Pearson’s Chi-squared test. Data were ana-
lysed in Stata/IC version 11.1 (StataCorp, College
Station, Texas, USA).
Ethics approval
The data presented here represent a collation of data
from women enrolled in treatment or in one preven-
tion trial in pregnancy all previously published and ap-
proved by the Faculty of Tropical Medicine Ethics
Committee in Bangkok and in later years the Oxford
Tropical Research Ethics Committee [6–11, 29].
Results
From December 1994 to November 2009, there were
700 women with 1,647 episodes of P. falciparum of
which 19 were classified as indeterminate by PCR; seven
failed to amplify; no PCR spot was found for two epi-
sodes and pregnancies with episodes of non-sequential
pairs were removed, leaving 1,609 episodes for analysis
in 700 women (Fig. 1). Most of the women, 691 (76.0 %),
experienced a single recurrence of P. falciparum during
their pregnancy, 164 (18.0 %) had two and 54 (6.0 %) expe-
rienced three or more recurrences within the same preg-
nancy. The maximum number of consecutive P. falciparumepisodes within a single pregnancy was five and all four re-
current infections could be characterized by PCR in two
women. The demographic characteristics of the pregnant
women at the time of the primary infection are reported in
Table 1.
Most of the recurrent infections, 85 % (770/909), oc-
curred following treatment with one of the three most
commonly used regimens: quinine monotherapy, arte-
sunate monotherapy or artesunate-clindamycin, which
are all rapidly eliminated seven-day treatments (Table 2).
Not all drugs were used for treatment across all years of
the data collection period, for example, mefloquine
monotherapy was only administered from 1994 to 1997
and in a very small number of women (Table 2). The
mean gestational age at the time of treatment was low-
est for quinine as it is the drug of choice for first trimes-
ter (Table 2). The number of recurrent infections
classified as recrudescent or novel varied with the anti-
malarial treatment provided (Table 2).
Table 2 Estimated gestational age and time to recurrence of Plasmodium falciparum (Pf) for novel and recrudescent infections for















% >28 days % >42 days % >63 days % (N)c
Quinine monotherapy
(short, 1994–2006)
476 17 [3–36] 173 47 [7–216] 303 21 [7–126] 25.4 (77/303) 10.6 (32/303) 5.0 (15/303) 33.0 (58)
Quinine + clindamycin
(short, 1998–2009)
29 10 [4–24] 22 84 [28–201] 7 50 [21–122] 57.1 (4/7) 57.1 (4/7) 42.9 (3/7) 7.4 (13)
Artesunate monotherapy
(short, 1995–2008)
151 21 [4–37] 102 54 [8–182] 49 22 [11–99] 30.6 (15/49) 12.2 (6/49) 4.1 (2/49) 21.6 (38)
Artesunate + Clindamycin
(short, 1998–2009)
143 23e [1–39] 121 49 [21–158] 22 28 [12–70] 45.5 (10/22) 27.3 (6/22) 9.1 (2/22) 26.1 (46)
Artemether + lumefantrine
(medium, 2004–2006)
43 23 [13–36] 24 36 [15–140] 19 23 [14–63] 31.6 (6/19) 26.3 (5/19) 0.0 (0/19) 6.3 (11)
Artesunate + Atovaquone + proguanil
(medium, 1999–2005)
11 23 [18–32] 8 67 [44–101] 3 49 [35–120] 100.0 (3/3) 66.7 (2/3) 33.3 (1/3) 1.7 (3)
Mefloquine monotherapy
(long, 1994–1997)
22 26 [12–38] 4 25 [9–44] 18 22 [7–123] 27.8 (5/18) 5.6 (1/18) 5.6 (1/18) 0 (0)
DHAf + Piperaquine
(long, 2006–2008)
29 20 [8–34] 23 63 [35–180] 6 33 [21–49] 66.7 (4/6) 16.7 (1/6) 0.0 (0/6) 4.0 (7)
Artesunate + Mefloquine
(long, 1995–2008)
5 28 [−0.4-39] 4 35 [20–43] 1 21 [−] 0.0 (0/1) 0.0 (0/1) 0.0 (0/1) 0 (0)
aaction, reflects length of time anti-malarial remains in the body after administration; years, period in which treatment was administered at SMRU
bN, number of recurrent Pf episodes
c% (N), percentage and number of intercalated P. vivax episodes
dEGA, estimated gestational age (weeks) at time of malaria episode
eone EGA missing
fDHA, dihydroartemisinin
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The geometric mean number of days to recurrence was
significantly shorter in women with recrudescent infec-
tion, 24.5 (95 %: 23.4-25.8) days, compared to re-
infection, 49.7 (95 %: 46.9-52.7) days, P <0.001 (Fig. 2).
There was no statistically significant difference in the
geometric mean number of days to recurrence according
to the episode number, i.e., for recurrent episodes that
were recrudescent infections, the time from the primary
infection to first recrudescence (N = 353) was 24 (95 %
CI: 23–26) days; first to the second recrudescence (N =
55) was 25 (95 % CI: 22–29) days; and, from the second
to the third or more recrudescence (N = 20) was 28
(95 % CI: 22–35) days, P = 0.44. For recurrent episodes
that were novel infections, the observed times were 50
(95 % CI: 46–53) days for primary to first (N = 339); 51
(95 % CI: 46–58) days first to second (N = 108); and, 45
(95 % CI: 38–53) days for second to third or more infec-
tion (N = 34), P = 0.38.
Time to recurrence with intercalated Plasmodium vivax
infection
Of the 909 P. falciparum recurrences, 19.3 % (176) had
an intercalated Plasmodium vivax infection between the
P. falciparum primary and recurrent episode. Therewere 145 recurrent P. falciparum episodes with one in-
tercalated P. vivax episode; and 23, seven and one with
recurrent P. falciparum episodes with two, three and five
intercalated P. vivax episodes, respectively. The propor-
tion of recrudescent P. falciparum infections following an
intercalated P. vivax infection was significantly lower than
those without an intercalated P. vivax episode: 19.9 % (35/
176) compared with 53.6 % (393/733), P <0.001. In both
novel and recrudescent infection, intercalated P. vivax in-
fection resulted in a longer geometric mean number of
days to recurrence compared to those without intercalated
P. vivax: 71 (95 % CI: 65–78) versus 43 (95 % CI: 40–46)
days, and 49 (95 % CI: 41–59) versus 23 (95 % CI: 22–24)
(P <0.001 for both), respectively. The proportion of inter-
calated P. vivax infections was lower with medium- and
long-acting anti-malarial treatments (Table 2).
Time to recurrence according to anti-malarial treatment
The geometric mean number of days to recrudescent infec-
tion(s) for short- (N = 381), medium- (N = 22) and long-
(N = 7) acting anti-malarials was 24 (95 % CI: 23–26), 28
(95 % CI: 25–33) and 33 (95 % CI: 26–43) days (linear
trend: P = 0.02), when mefloquine monotherapy was ex-
cluded from the analysis (only used from 1994–97, but high
grade resistance was already established during this period).
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ric mean number of days to recrudescent infection for
long-acting anti-malarials fell to 25 (95 % CI: 20–32) days
and the linear trend was no longer significant (linear trend:
P = 0.85). There was no evidence of a linear trend in num-
ber of days to novel infection for short-, medium- and
long-acting anti-malarials.
Recrudescence after 28, 42 and 63 days of follow-up in
pregnancy
Nearly one third 29 % (124/428) of recrudescent infec-
tion occurred after day 28 with 13.3 % (57/428) and
5.6 % (24/428) occurring after day 42 and 63, respect-
ively. The proportion of quinine treatments that were
true recrudescent infections that would be wrongly clas-
sified as ‘treatment success’, if follow-up ceased at day
28, day 42 and day 63 were 26.1 % (81/310), 11.6 % (36/
310) and 5.8 % (18/310), respectively (Table 2). For
artemisinin-based treatments the respective proportions
were 38.0 % (38/100), 20.0 % (20/100) and 5 % (5/100)
(Table 2).
Factors associated with time to a recrudescent infection
For four anti-malarial treatments (quinine and meflo-
quine monotherapy, quinine + clindamycin and artesu-
nate + atovaquone + proguanil), women were observed
to have recrudescent infections 100 or more days from
the start of drug treatment (Table 2). There were noTable 3 The estimated ratio of the geometric mean number of day
regression analyses of 428 Plasmodium falciparum episodes among
Univariablea
Risk factor Categories Nb Ratio of geometric mea
Parity Primiparous 93 0.99 (0.86, 1.14) [0.890]
Multiparous 256 1c
Anti-malarial therapy Artemisinin based 49 1.28 (1.09, 1.51) [0.003]
Non-artemisinin based 300 1
Symptoms Symptomatic 232 0.89 (0.77, 1.03) [0.120]
Asymptomatic 88 1
Therapy supervision Unsupervised 86 0.83 (0.73, 0.94) [0.004]
Supervised 253 1
Intercalated P. vivax Yes 28 2.19 (1.77, 2.72) [<0.001]
No 321 1
EGA (weeks) 349 349 1.00 (0.99, 1.00) [0.217]
Parasitaemia (m/L)d 349 349 0.98 (0.97, 1.00) [0.079]
Haematocrit (%) 327 327 1.00 (0.99, 1.01) [0.618]
Combo, combination; Mono, monotherapy
aOutcome is time to recrudescent infection and estimates are adjusted for age, wei
age, weight and study period; Multivariable, linear model included all risk factors, a
bThe total number of episodes (N) included in each analysis may differ from 428 du
cIndicates reference group
dParasitaemia was log2 transformed. Estimate interpreted as a 0.98-fold decrease in
in parasitaemiaintercalated P. falciparum recrudescent infections (i.e.,
a recrudescence of a primary infection after an inter-
vening novel infection).
Estimated ratios of geometric means are presented in
Table 3 for eight risk factors hypothesized to be associ-
ated with the number of days to recrudescent P. falcip-
arum infection. Of the eight risk factors, anti-malarial
therapy, therapy supervision, intercalated P. vivax infec-
tion, and initial parasitaemia were found to be associated
with number of days to recrudescent infection P <0.1, in
linear regression analyses, including a single risk factor
and adjusting for age, weight and study period (see
Table 3 column ‘Univariable’). These variables remained
associated at the nominal level of significance of 0.1, in a
linear regression analysis including all risk factors and
adjusting for age, weight and study period (see Table 3 col-
umn ‘Multivariable’). The estimated ratio of geometric
means for the statistically, significantly associated, risk fac-
tors obtained from the multivariable analysis suggests an
increase in the geometric mean number of days to recru-
descent infection of 1.28-fold (95 % CI: 1.09-1.51) for
women treated with artemisinin based therapy compared
to non-artemisinin based therapy; and 2.19-fold (95 % CI:
1.77-2.72) in those women with an intercalated P. vivax
infection compared to those who did not have intercalated
P. vivax. A decrease in the geometric mean number of
days to recrudescent infection of 0.83-fold (95 % CI: 0.73-
0.95) was observed for women whose treatment wass to recrudescence for each risk factor derived from linear
354 pregnant women
Multivariablea
ns (95 % CI) [P-value] Nb Ratio of geometric means (95 % CI) [P-value]
79 1.03 (0.89, 1.19) [0.698]
212 1
38 1.24 (1.07, 1.43) [0.003]
253 1
211 0.94 (0.80, 1.11) [0.459]
80 1
81 0.83 (0.73, 0.95) [0.006]
210 1
25 2.19 (1.76, 2.73) [<0.001]
266 1
291 1.00 (0.99, 1.00) [0.210]
291 0.98 (0.96, 0.99) [0.014]
291 1.00 (0.99, 1.01) [0.654]
ght and study period. Univariable, linear model included a single risk factor,
ge, weight and study period
e to missing risk factor data
geometric mean time to recrudescent Pf infection(s) for a doubling
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vised; and 0.98-fold (95 % CI: 0.96-0.99) for each doubling
in the baseline parasitaemia.
Discussion
This study reports the largest, single-site, longitudinal
population study of PCR-genotyped P. falciparum mal-
aria parasitaemia in pregnancy.
Prolonged carriage in pregnant women
The interval from treatment of falciparum malaria in
pregnancy to PCR-confirmed recrudescent infection can
be prolonged. The maximum observed time in this large
dataset was 126 days. Pregnant women in this study gen-
erally received supervised rather than unsupervised
treatment of P. falciparum. Supervising the treatment
was associated with an increased interval to late recru-
descence. Several factors contributed to the high rates of
recrudescence. While all women were treated with
standard adult dosing of anti-malarials, pregnancy alters
the pharmacokinetic properties of many anti-malarials
lowering their plasma concentrations [17, 18]. It has
been hypothesized that artesunate-treated parasites may
enter a state of quiescence, which protects them from
the lethal effects of anti-malarials but later allows recov-
ery and normal growth [30, 31]. Dormancy has also been
postulated to occur with pyrimethamine, atovaquone
and proguanil [32, 33]. However, in this cohort, combin-
ation therapy whether artesunate-based or not was as-
sociated with a longer time to recrudescent infection.
Immunity to malaria is reduced in pregnancy and the pla-
centa provides a favourable site for the parasite to seques-
ter where host defence mechanisms are attenuated [34].
Intercalated P. vivax infection resulted in a signifi-
cantly lower proportion of recrudescent P. falciparum
episodes than in women who did not have intercalated
P. vivax. Intercalated P. vivax prolonged the time to re-
currence of both novel and recrudescent infections and
was the most significant risk factor for prolonged time
to recrudescence. Although the chloroquine inhibitory
concentration of 50 % (IC50) for P. falciparum isolates
in this area are amongst the highest reported in the
world [35, 36] some isolates are still partially sensitive to
chloroquine. This is consistent with results that demon-
strated a non-significant reduction in P. falciparum in a
double-blind, randomized, placebo-controlled, prophy-
laxis trial of 1,000 pregnant women in this setting [29].
In addition, P. vivax may activate host-defences which
affect P. falciparum [37]. The two parasites are competi-
tive and provide mutual suppression. A protective effect
of P. vivax has previously been reported in this area:
mixed (P. falciparum and P. vivax) infection was associ-
ated with a four-fold reduction in the risk of developing
severe malaria [22].Pregnancy and anti-malarial efficacy
The proportion of recrudescent infections with quinine
and mefloquine monotherapy was high and these poorly
efficacious regimens should no longer be used in this
area [6, 7]. Patent and sub-patent P. falciparum parasit-
aemia in pregnancy are harmful to the pregnant woman
and the foetus and prompt and efficacious treatment is
required [38]. Frequent screening of a woman during
pregnancy will increase the detection of parasitaemia [2].
Treatment of these episodes reduces but does not elim-
inate the adverse effects of low birth weight for the
foetus and anaemia for the mother [2], which can only
be achieved by prevention.
This study demonstrates that a significant proportion
of pregnant women, 29.0 % by day 28, 13.3 % by day 42
and 5.6 % by day 63 of follow-up, have recrudescent in-
fections beyond the traditional boundaries used for
follow-up in anti-malarial efficacy trials. These propor-
tions are large enough to underestimate significantly
true failure rates with shorter periods of follow-up. Ac-
curate assessment of anti-malarial efficacy in pregnancy
requires follow-up to delivery, failing this, day 63. This is
contrary to modelling data from trials in non-pregnant
patients where 42–63 days follow-up captures nearly all
anti-malarial treatment failures [4].
There are limitations to this analysis: only three drug
treatments (quinine monotherapy, artesunate monother-
apy and artesunate clindamycin) accounted for 85 % of
the data. In this setting, with MDR-P. falciparum no trial
that includes both pregnant and non-pregnant women has
been conducted. Attempts to pool data on recrudescent P.
falciparum infections for age-matched women of repro-
ductive age treated with the same anti-malarial and same
year of treatment within the population, i.e., artemether-
lumefantrine and dihydroartemisinin-piperaquine, were
unsuccessful.
While there are reasons to suspect that pregnancy per
se many predispose to a longer duration to recrudes-
cence this study is unable to prove it. Only settings with
data including prolonged duration of follow-up; the
same regimen for diagnosis and treatment of P. falcip-
arum infections in pregnant and non-pregnant women
which is most often not the case; and preferably with
women matched for age and gravidity would have the
potential to elucidate this suspicion.
Post-treatment prophylactic effect
No effect of anti-malarial drugs was observed on the
post-treatment prophylactic effect, i.e., the time to novel
recurrence however without a group who receives no
anti-malarials this cannot be proven. There was limited
power to detect a post-treatment prophylactic effect and
there were few patients who received long-acting anti-
malarials and re-infection rates were very low, so any
Laochan et al. Malaria Journal  (2015) 14:221 Page 8 of 9effect would have been small. Regarding IPT in this area
a study conducted in men followed for nine months in
a randomized, placebo controlled IPT trial required
dihydroartemisinin-piperaquine to be provided monthly
at full treatment doses (two tablets twice per day for
three days) to be effective [39]. When re-infection rates
of P. falciparum are very low it is difficult to justify the
use of IPT as the risk benefit ratio may not be in favour
of providing this drug to all pregnant women. The
current annual incidence of P. falciparum in pregnancy
in the area is now less than 0.5 infections per woman
per year [40].
Conclusion
The interval to recrudescence of falciparum malaria in
pregnancy can be prolonged, regardless of the anti-
malarial used for treatment. In areas where intercalated
P. vivax occurs and receives treatment, time to recrudes-
cence of P. falciparum can be prolonged. In this area of
low, seasonal malaria transmission, recrudescence oc-
curred after day 42 in approximately 15 % and after day
63 in 5 %, of pregnant women. Accurate characterization
of drug efficacy in pregnancy requires follow-up to deliv-
ery or day 63, whichever occurs last.
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